Search
Tonsillitis Chronic
go.drugbank.com/conditions/DBCOND0113605Drugs: XibornolSynonyms: Chronic tonsillitis and adenoiditisDesogestrel
go.drugbank.com/drugs/DB00304ApprovedInvestigational[A176342] The first approved drug containing desogestrel was developed by Organon USA Inc in 1972 and FDA approved in 1992.[L5762] … Desogestrel, a prodrug, is a third generation progestogen[A176315] and hence, a member of the gonane family which was largely used in Europe before being approved in the US and Canada.
Synonyms: 13-Ethyl-11-methylene-18,19-dinor-17α-pregn-4-en-20-yn-17-olMixtures: Desogestrel and Ethinyl Estradiol and Ethinyl Estradiol, Desogestrel and Ethinyl Estradiol and Ethinyl EstradiolAcetarsol
go.drugbank.com/drugs/DB13268ApprovedWithdrawn[L2622] It was first discovered in 1921 by Ernest Fourneau at the Pasteur Institute. It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964. … It has been canceled and withdrawn from the market since August 12, 1997.[L1113]
Categories: Alimentary Tract and Metabolism, Genito Urinary System and Sex HormonesGastric intrinsic factor
go.drugbank.com/drugs/DB09349ApprovedHowever, it is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic Vitamin B12), ferrous fumarate, and ascorbic acid for the treatment of anemias … Intrinsic factor is not currently available in any FDA or Health Canada approved products.
Mixtures: Iron Aspartate, Glycinate, Ascorbic Calcium, Vitamin B12, Calcium Threonate and Succinic Acid, EnLyte Extra-LNCategories: Amino Acids, Peptides, and ProteinsCag alpha
go.drugbank.com/bio_entities/BE0002850TargetHelicobacter pyloriPolypeptides: Cag alphaSynonyms: Cag-alfa, cag-alphaSotagliflozin
go.drugbank.com/drugs/DB12713ApprovedInvestigational[L39734] A similar approval has also been sought in the US, but the FDA has since published a proposal to refuse the approval because the data submitted did not show that it was safe under the proposed … [L39705] Its potency in inhibiting SGLT2 is similar to that of other SGLT2 inhibitors, such as [canagliflozin] and [dapagliflozin], but its potency in inhibiting SGLT1 is >10-fold higher than its predecessors
Categories: Alimentary Tract and Metabolism, Drugs Used in DiabetesAcute Pelvic inflammatory disease
go.drugbank.com/conditions/DBCOND0022868Drugs: OfloxacinSynonyms: Acute pelvic inflammatory disease of the female pelvic organs and tissues, Acute pelvic inflammatory disease of the female pelvic organs AND/OR tissuesFacial Angiofibroma
go.drugbank.com/conditions/DBCOND0063101Drugs: SirolimusSynonyms: Angiokeratoma in tuberous sclerosisDysuria
go.drugbank.com/conditions/DBCOND0004536Synonyms: Difficulty in voiding, Difficulty in urinationDurvalumab
go.drugbank.com/drugs/DB11714ApprovedInvestigational[A192789,L12627] On March 27, 2020, durvalumab was approved by the FDA for use in combination with [etoposide] and either [carboplatin] or [cisplatin] as first-line treatment of patients with extensive-stage … [L12621] In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating Agents